Share this article
Share this article
BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM). This technology comes out as a valuable time-saver, supporting the management of adverse drug reaction (ADR) reports by making it easier and allowing pharmacovigilance teams to focus their attention on the
most severe cases. Because COVID-19 vaccines were developed in a brief period of time, it is crucial to ensure rigor and responsiveness in monitoring any possible side-effects.
E-Mail
What The Study Did: This study quantified changes in the use of intravitreal (IVT) anti-vascular endothelial growth factors (anti-VEGF), the main treatment for retinal vascular abnormalities, since the COVID-19 pandemic started in France.
Authors: Sophie Billioti de Gage, Pharm.D., P.D., of EPI-PHARE, French National Agency for Medicines and Health Products Safety, French National Health Insurance in Saint-Denis, France, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/